New hypertension guidelines set aggressive goals based on risk factors

Cleveland Clinic Journal of Medicine

Volumn 65, Issue 1, 1998, Pages 18-24

  Gifford Jr , Ray W ^a,b,c,d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c National Hypertension Association

^d D ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; CYCLOSPORIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; IMMUNOSUPPRESSIVE AGENT; LOSARTAN; METHYLDOPA; METOPROLOL; NADOLOL; PROPRANOLOL; RESERPINE; THIAZIDE DIURETIC AGENT; TIMOLOL; VERAPAMIL;

ACUTE HEART INFARCTION; ALGORITHM; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CIGARETTE SMOKING; DIABETES MELLITUS; DRUG CONTRAINDICATION; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FAMILY HISTORY; HEART FAILURE; HUMAN; HYPERTENSION; LIFESTYLE; MANAGED CARE; REVIEW; RISK FACTOR; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 2642707546     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.65.1.18     Document Type: Review

References (11)

1. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
2. National Heart, Lung, and Blood Institute. Fact Book Fiscal Year 1996. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, 1997.
3. US Renal Data System. USRDS 1997 Annual Report. Bethesda, MD: US Department of Health and Human Services, National Institute of Diabetes and Digestive and Kidney Disease, 1997.
4. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996; 275:1557-1562.
5. National Center for Health Statistics. Health, United States, 1996. Hyattsville, MD: Public Health Service, 1997.
6. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on primary prevention of hypertension. Arch Intern Med 1993; 153:186-208.
7. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-183.
8. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9:342-360.
9. Edelson JT, Weinstein MC, Tosteson ANA, et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990; 263:407-413.
10. Jönsson BG. Cost-benefit of treating hypertension. J Hypertens 1994; 12(suppl 10):S65-S70.
11. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 1995; 7:242-250.